Importantly, these medications carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Tirzepatide, with a dual activity target GIP and GLP1 receptor, may have consequences for preventing or mitigating atherosclerosis due to its impact on GIPR activity
Wang C, Yuan W, Hu A, Lin J, Xia Z, Yang CF, et al
They may recommend alternative wellness therapies
Treatment of alcohol-related liver disease with thioctic acid: a six-month, randomized, double-blind trial
Misleading labeling is common